Literature DB >> 31262867

Biochemical Inhibition of DOG1/TMEM16A Achieves Antitumoral Effects in Human Gastrointestinal Stromal Tumor Cells In Vitro.

Robin Fröbom1, Felix Sellberg2, Cheng Xu3, Allan Zhao3, Catharina Larsson4,5, Wenn-Onn Lui4,5, Inga-Lena Nilsson6, Erik Berglund7, Robert Bränström6.   

Abstract

BACKGROUND/AIM: DOG1 is a calcium-activated chloride channel that has gained attention as a promising drug target due to its involvement in several processes essential for tumor development and progression. DOG1 is overexpressed in >95% of gastrointestinal stromal tumors (GIST). The aim was to determine DOG1 inhibition antitumoral effects on GIST.
MATERIALS AND METHODS: Human GIST (GIST-T1 and GIST882) cell lines were used to study the effect of DOG1 inhibitors on chloride currents, viability, colony formation, and cell cycle.
RESULTS: CaCCinh-A01 decreased chloride currents. CaCCinh-A01 and T16inh-A01 reduced GIST cell viability and CaCCinh-A01 affected cell cycle distribution leading to G1 cell-cycle arrest. CaCCinh-A01 also increased the sub-G1 phase population, indicative of apoptosis, in GIST882. CaCCinh-A01 strongly reduced the colony forming ability of the cells, whereas T16inh-A01 did not.
CONCLUSION: DOG1 inhibition has antitumoral effects in GIST cells in vitro, and could potentially serve as a target for GIST therapy. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  DOG1; GIST; Gastrointestinal stromal tumors; TMEM16A; cancer; ion channel

Mesh:

Substances:

Year:  2019        PMID: 31262867     DOI: 10.21873/anticanres.13489

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Role of ANO1 in tumors and tumor immunity.

Authors:  Haini Li; Zongxue Yu; Haiyan Wang; Ning Wang; Xueguo Sun; Shengmei Yang; Xu Hua; Zongtao Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-26       Impact factor: 4.322

2.  DOG1 overexpression is associated with mismatch repair deficiency and BRAF mutations but unrelated to cancer progression in colorectal cancer.

Authors:  Kristina Jansen; Martina Kluth; Niclas C Blessin; Claudia Hube-Magg; Michael Neipp; Hamid Mofid; Hannes Lárusson; Thies Daniels; Christoph Isbert; Stephan Coerper; Daniel Ditterich; Holger Rupprecht; Albert Goetz; Christian Bernreuther; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Eike Burandt; Daniel Perez; Jakob R Izbicki; Frank Jacobsen; Till S Clauditz; Andreas H Marx; Till Krech
Journal:  Histol Histopathol       Date:  2022-06-01       Impact factor: 2.130

3.  DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness.

Authors:  Kristina Jansen; Franziska Büscheck; Katharina Moeller; Martina Kluth; Claudia Hube-Magg; Niclas Christian Blessin; Daniel Perez; Jakob Izbicki; Michael Neipp; Hamid Mofid; Thies Daniels; Ulf Nahrstedt; Christoph Fraune; Frank Jacobsen; Christian Bernreuther; Patrick Lebok; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Eike Burandt; Andreas Marx; Till Krech; Till Clauditz
Journal:  PeerJ       Date:  2021-08-03       Impact factor: 2.984

4.  ANO1: More Than Just Calcium-Activated Chloride Channel in Cancer.

Authors:  Saisai Guo; Linna Zhang; Na Li
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

Review 5.  The Ca2+-activated chloride channel ANO1/TMEM16A: An emerging therapeutic target for epithelium-originated diseases?

Authors:  Yani Liu; Zongtao Liu; KeWei Wang
Journal:  Acta Pharm Sin B       Date:  2020-12-09       Impact factor: 11.413

6.  Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors.

Authors:  Daniela Gasparotto; Marta Sbaraglia; Sabrina Rossi; Davide Baldazzi; Monica Brenca; Alessia Mondello; Federica Nardi; Dominga Racanelli; Matilde Cacciatore; Angelo Paolo Dei Tos; Roberta Maestro
Journal:  JCI Insight       Date:  2020-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.